Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1760

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Thierry Guillaume, MD PhD, Pierre Peterlin, Sylvain Thepot, MD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Sylvie François, MD, Corentin Orvain, Yannick Le Bris, PharmD, Clémentine Fronteau, PharmD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 4555.

https://doi.org/10.1182/blood-2019-123402

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Ali Sakhdari, MD MSc, Caleb Class, PhD, Guillermo Montalban-Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Joseph D. Khoury, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, L. Jeffrey Medeiros, MD, Rashmi Kanagal-Shamanna, MD

Blood (2019) 134 (Supplement_1): 3016.

https://doi.org/10.1182/blood-2019-131774

Published: 2019

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3002.

https://doi.org/10.1182/blood-2019-129906

Published: 2019

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Irene Ganan-Gomez, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Kiran Naqvi, MDMPH, Yue Wei, PhD, Hui Yang, PhDMD, Kelly Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Kim-Anh Do, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 3006.

https://doi.org/10.1182/blood-2019-124957

Published: 2019

Journal Articles

Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes

Lingxu Jiang, Yingwan Luo, Jie Jin, MD PhD, Hongyan Tong

Blood (2019) 134 (Supplement_1): 3008.

https://doi.org/10.1182/blood-2019-125660

Published: 2019

Journal Articles

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Eun-Ji Choi, MD, Young-Uk Cho, MD, Seongsoo Jang, Chan-jeoung Park, Han-Seung Park, MD, Jung-Hee Lee, MD PhD, Kyoo-Hyung Lee, MD PhD, Eun-Hye Hur, PhD, Nayoung Kim, PhD, Hee Jeong Ouk, MD, Je-Hwan Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3009.

https://doi.org/10.1182/blood-2019-125236

Published: 2019

Journal Articles

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Maria Julia Montoro, MD, Ana Perez, MD, Silvia Saumell, MD PhD, Maida Navarrete, MD, Gael Roue, PhD, Moraima Jimenez, MD, Margarita Ortega, PhD, Bárbara Tazón, PhD, Antonieta Molero, MD, Olga Salamero, MD, Francesc Bosch, MD PhD, David Valcarcel, MD

Blood (2019) 134 (Supplement_1): 3011.

https://doi.org/10.1182/blood-2019-123185

Published: 2019

Journal Articles

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Blood (2019) 134 (Supplement_1): 3012.

https://doi.org/10.1182/blood-2019-123684

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes

Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes

Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R

Morphologic Assessment of Terminal Erythroid Differentiation Predicts Outcomes in Myelodysplastic Syndromes

Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only